Patent · US Active

PZA and cytochrome Bc1 inhibitor combination treatment

US11918575B2 · kind B2 · utility

0Cited by
4References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 2, 2021
Grant dateMar 5, 2024
Priority date
Expiry dateFeb 11, 2042

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P31/06
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.